Savannah Environmental Nutrition Study (SENS): Nutrition Intervention to Reduce Air Pollution-Related Airway Inflammation and Oxidative Stress

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGeorgia Southern University

About this trial

This pilot clinical trial will evaluate the feasibility and potential health effects of a nutrition-based intervention among adults living in communities affected by air pollution near the Port of Savannah, Georgia. Participants will be assigned to either a nutrition intervention group or a control group. The intervention group will receive biweekly grocery deliveries emphasizing foods naturally rich in antioxidants and anti-inflammatory nutrients, including vitamins C and E, omega-3 fatty acids, and polyphenols. The control group will continue their usual dietary practices during the study period.

The study will evaluate whether the nutritional intervention is associated with changes in selected respiratory, oxidative stress, and cardiometabolic health indicators. Assessments will include fractional exhaled nitric oxide (FeNO) as a marker of airway inflammation, hydrogen peroxide (H₂O₂) in exhaled breath condensate as a marker of oxidative stress, systolic and diastolic blood pressure, resting heart rate, and glycated hemoglobin (HbA1c). Indoor concentrations of particulate matter (PM), nitrogen dioxide (NO₂), and ozone (O₃) will also be monitored to characterize participants' household air-pollution exposures. Measurements will be collected at baseline and at subsequent study assessments, as specified for each outcome. Findings from this pilot study will be used to evaluate feasibility, estimate changes in health outcomes, and inform the design of a larger clinical trial investigating nutritional approaches to potentially reduce health effects associated with air-pollution exposure.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Residing in Port Wentworth or the Savannah main Channel at a 3-mile radius for the prior 12 months and not planning to move during the study.

Non-smoking status (or specified ANY smoking history)

Absence of pre-existing chronic respiratory conditions (Asthma, Chronic Obstructive Pulmonary Disease, Seasonal respiratory allergies that require the use of antihistamines or immunosuppressants more than once a month, Chronic Bronchitis, and Heart Failure or any condition that would put participants at a greater risk than other participants for a pre-existing condition.

Willingness and ability to participate in home monitoring protocols

Disqualifiers

Individuals unable to follow study procedures

Antihistamines or any immunosuppressors, ongoing cancer treatment or within the past 5 years

Individuals unable to read, speak, and/or understand English or Spanish

Any food allergy

Trial design

Design model

Parallel

Treatments tested in this trial

  • Antioxidant- and Nutrient-Rich Food-Based Nutrition Intervention

    Other intervention

    Participants assigned to the intervention will receive biweekly grocery deliveries containing selected foods naturally rich in antioxidant and anti-inflammatory dietary components, including vitamins C and E, omega-3 fatty acids, and polyphenols. Participants will receive guidance on incorporating the provided foods into their usual dietary patterns. The intervention is designed to increase consumption of nutrient-rich foods and to evaluate the feasibility and potential effects of this dietary approach on respiratory inflammation, oxidative stress, and cardiometabolic outcomes among adults living in a community affected by air pollution.

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Nutrition InterventionExperimental treatment 1 intervention
Group B: Control GroupNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Participant Retention Rate

Through the Final Assessment Participant retention will be assessed as the proportion of enrolled participants who complete the study through the final Week 12 assessment. Retention rate will be calculated as the number of enrolled participants who complete the final assessment, divided by the total number of participants enrolled at baseline, multiplied by 100. A retention rate of ≥80% will be considered evidence of acceptable feasibility for a future larger-scale trial.

Time frame
Baseline through Week 12.

Secondary outcomes

1

Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO)

Fractional exhaled nitric oxide (FeNO) will be measured in parts per billion (ppb) using the NIOX Mini device as a non-invasive marker of airway inflammation. FeNO will be assessed using standardized procedures, and changes over time will be compared between the nutrition intervention and control groups.

Time frame
Baseline, approximately Week 6, and Week 12
2

Change From Baseline in Hydrogen Peroxide (H₂O₂) Concentration in Exhaled Breath Condensate

Hydrogen peroxide (H₂O₂) concentration in exhaled breath condensate (EBC) will be measured as a non-invasive marker of respiratory oxidative stress. EBC will be collected using the RTube® collection system, and H₂O₂ concentration will be quantified using the Amplex™ Red Hydrogen Peroxide/Peroxidase Assay with fluorescence detection. H₂O₂ concentrations will be reported in micromolar (µM) units. Changes from baseline will be evaluated over the intervention period and compared between the nutrition intervention and control groups.

Time frame
Baseline, approximately Week 6, and Week 12
3

Change From Baseline in Systolic Blood Pressure

Systolic blood pressure will be measured in millimeters of mercury (mmHg) using a validated automatic upper-arm blood pressure monitor. Participants will obtain two measurements approximately one minute apart after at least five minutes of seated rest, and the average of the two measurements will be used for analysis.

Time frame
Baseline, approximately Week 6, and Week 12
4

Change From Baseline in Diastolic Blood Pressure

Diastolic blood pressure will be measured in millimeters of mercury (mmHg) using a validated automatic upper-arm blood pressure monitor. Two measurements approximately one minute apart will be obtained after at least five minutes of seated rest, and the average will be used for analysis.

Time frame
Baseline, approximately Week 6, and Week 12

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: